Apr 18, 2024 · In the context of cancer, MRD-testing attempts to quantify residual cancer cells when the cancer is no longer detectable by conventional methods including blood tests, biopsy or radiological...

Jun 27, 2024 · Starting from modestly accurate assays for measurable residual disease (MRD), testing is being used at many centres and available from commercial laboratories. The hope is results of these...

We review concepts underlying MRD-testing and results of studies of MRD-testing in haematological and solid cancers.

Minimal residual disease (MRD) refers to a very small number of residual tumor cells in the body during or after treatment, representing the persistence of the tumor and the possibility of clinical progress.

Nov 1, 2024 · MRD-testing refers to quantification of residual cancer cells or surrogate markers of cancer cells when there is histological complete remission after a therapy-intervention, i.e. residual cancer cells cannot be detected by conventional techniques.

We review MRD-testing technologies and evaluate the accuracy of MRD-testing for predicting relapse and the strength of evidence supporting efficacy of MRD-guided therapy. We show that at the individual level MRD-test results are often an inaccurate relapse predictor.

Apr 18, 2024 · However, an updated critical evaluation of using MRD-tests to predict cancer recurrence and to direct subsequent cancer therapy(ies) is needed. We review concepts underlying MRD-testing and results of studies of MRD-testing in …

Affiliations 1 State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China. [email protected].; 2 Tianjin Institutes of Health Science, Tianjin, China. [email protected].

There is considerable interest in developing techniques to detect and/or quantify remaining leukaemia cells termed measurable or, less precisely, minimal residual disease (MRD) in persons with acute myeloid leukaemia (AML) in complete remission defined by cytomorphological criteria.

Sep 13, 2023 · There is considerable interest in tests quantifying remaining leukaemia cells after therapy, termed measurable residual disease (MRD)-tests, to predict therapy outcomes, leukaemia...